A Single-Blind, Randomized, Placebo Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Healthy Normal Subjects.
Phase of Trial: Phase I
Latest Information Update: 11 Jul 2017
At a glance
- Drugs GSK 1362885 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 15 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Feb 2009 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.